- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib, Oleclumab, Trastuzumab deruxtecan, Cediranib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 17
- States / cities
- Duarte, California • Fullerton, California • La Jolla, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1681–1704
of 11,377
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Epilepsy
- Interventions
- Lacosamide
- Drug
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- 1 Month to 16 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Loxahatchee Groves, Florida + 7 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Doxorubicin, Cytarabine, Methotrexate, Vincristine, Cyclophosphamide, Methylprednisone, Hydrocortisone Sodium Succinate, Dexamethasone, 6-MP, PEG-Asparaginase, Imatinib, Etoposide, Radiation Therapy, E. coli Asparaginase
- Drug · Procedure
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • New York, New York • Columbus, Ohio + 1 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- rRSV A/Maryland/001/11
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease, Retinal Degeneration
- Interventions
- GEM103
- Drug
- Lead sponsor
- Gemini Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 26 more
- Conditions
- HER2-negative Metastatic Breast Cancer
- Interventions
- DAN-222, Niraparib
- Drug
- Lead sponsor
- Dantari, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 9
- States / cities
- La Jolla, California • Santa Monica, California • Tampa, Florida + 6 more
- Conditions
- Focal Epilepsy, Temporal Lobe Epilepsy, Medically Refractory Epilepsy, Memory Disorders, Epilepsy Comorbidities, Epilepsy Intractable, Epilepsy Surgery, Epilepsy, Temporal Lobe, Memory Deficits, Memory Disorder, Spatial, Memory Dysfunction, Spatial Perception
- Interventions
- Virtual Tour Recognition Memory Task, Intracranial EEG Recording with Research Electrodes (Aim III only), MRI Neuroimaging and Neuropsychological Assessment (Aim I)
- Behavioral · Device · Diagnostic Test
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- Sacramento, California • Atlanta, Georgia
- Conditions
- Somatic Pain
- Interventions
- low-intensity focused ultrasound - low pressure, low-intensity focused ultrasound - medium pressure, low-intensity focused ultrasound - high pressure
- Device
- Lead sponsor
- Virginia Polytechnic Institute and State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Roanoke, Virginia
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
- Interventions
- SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine, SOC, Antiandrogen
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Baltimore, Maryland • Rochester, Minnesota + 3 more
- Conditions
- Blood Cholesterol, Blood Pressure Monitoring, Weight Change, BMI, Diabetes Education, Diabetes (DM)
- Interventions
- Remote Patient Monitoring in a Faith-Based Program, Traditional Cohort Faith-based DSMES program
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- COVID, COVID19, SARS-CoV 2, Dyspnea
- Interventions
- Data Collection
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11,973 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma, Rare Lesion, Locally Advanced Malignant Neoplasm, Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Malignant Neoplasm, Metastatic Skin Squamous Cell Carcinoma, Metastatic Small Intestinal Adenocarcinoma, Rare Neoplastic Syndrome, Refractory Malignant Neoplasm, Stage IV Small Intestinal Adenocarcinoma AJCC v8, Unresectable Malignant Neoplasm
- Interventions
- Atezolizumab, Cobimetinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Unresectable Hepatocellular Carcinoma (HCC)
- Interventions
- NMS-01940153E
- Drug
- Lead sponsor
- Nerviano Medical Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Orange, California • St Louis, Missouri
- Conditions
- Castrate Resistant Prostate Cancer (CRPC)
- Interventions
- BPX-101, AP1903
- Biological · Drug
- Lead sponsor
- Bellicum Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- lenalidomide, rituximab, pharmacological study, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cataract, Age-related Cataract, Circadian Rhythm Disorders, Glaucoma, Age Related Macular Degeneration
- Interventions
- Blue-light filtering intraocular lens, Conventional intraocular lens
- Device
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 10,192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Epilepsy; Seizure
- Interventions
- Oral 2-Deoxy-D-Glucose (2DG)
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Pompe Disease
- Interventions
- rAAV1-CMV-GAA (study agent) Administration, RMST
- Drug · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- AML, Adult Recurrent, ALL, Recurrent, Adult, MDS
- Interventions
- SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose
- Drug
- Lead sponsor
- BlueSphere Bio, Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 6
- States / cities
- Duarte, California • Tampa, Florida • Ann Arbor, Michigan + 3 more
- Conditions
- Acute Compartment Syndrome
- Interventions
- Near infrared spectroscopy (NIRS)
- Device
- Lead sponsor
- J&M Shuler
- Industry
- Eligibility
- 15 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Healthy Volunteers, Moderate to Heavy Smokers, Non-smokers
- Interventions
- pracinostat
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Urothelial Cancer, Poorly Differentiated Neuroendocrine Carcinomas, Homologous Recombination Deficient-Positive Malignancies Agnostic
- Interventions
- Lurbinectedin
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 17
- States / cities
- Stanford, California • Norwich, Connecticut • Fort Myers, Florida + 14 more
- Conditions
- Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
- Interventions
- Cabozantinib, Topotecan, Cyclophosphamide, Myeloid growth factor
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 6 Years to 30 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Neoplasms
- Interventions
- Axitinib + Paclitaxel + Carboplatin (Cohort 1), Axitinib + Paclitaxel + Carboplatin (Cohort 2), Axitinib + Paclitaxel + Carboplatin (Cohort 3), Axitinib + Paclitaxel (Cohort 4), Axitinib + Docetaxel + Carboplatin (Cohort 4a), Axitinib + Docetaxel (Cohort 5), Axitinib + Capecitabine (Cohort 6), Axitinib + Capecitabine (Cohort 7), Axitinib + Gemcitabine + Cisplatin (Cohort 8), Axitinib + Pemetrexed + Cisplatin (Cohort 9)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 10
- States / cities
- Augusta, Georgia • Harvey, Illinois • Tinley Park, Illinois + 5 more